Features of clinical and anamnestic characteristics and treatment of patients with hypertriglyceridemia (the data from Kuzbass register of dyslipidemias)

Aim. To study the features of clinical and anamnestic characteristics and treatment of patients with hypertriglyceridemia (HTG) using the data of the lipid control center of Kemerovo.

Methods. The single-center retrospective study is based on the data of patients dynamic observation (n = 100) in the Dyslipidemia Registry of Kuzbass in 2019. A comparative analysis of clinical and anamnestic characteristics, lipidogram parameters and therapy was performed at the time when the patients were included in the study and after 6–12 months in patients with HTG (the criterion was the level of triglycerides (TG) above 1.69 mmol/L) and in patients without it. Indications for consulting a lipidologist were high cholesterol (levels of total cholesterol (TC) ˃7.5 mmol/L or low-density lipoprotein cholesterol ˃4.9 mmol/L or TG˃5 mmol/L), requirement of the high dose and/or combination therapy of lipid-lowering drugs; medical history of cardiovascular diseases and/or revascularization of vascular bed in patients under 55 years of age; suspected intolerance to lipid-lowering therapy due to the developed side effects; the issue of lipid-lowering therapy in complex clinical situations.

Results. Among the patients who visited a lipidologist in 2019, mixed hypertriglyceridemia was noted in 56 (56%) of cases, while 44 (44%) patients had other lipid metabolism disorders without increased levels of TG. A distinctive feature of patients with mixed hypertriglyceridemia is the lower incidence of myocardial infarctions (p = 0.029) and lower number of coronary stents (p = 0.018) in the medical history, despite the initially higher levels of TC (p = 0.005) and TG (p = 0.000). According to the results of 6–12 months observation, a significant decrease in TC (p = 0.001) and TG (p = 0.044) levels during the lipid-lowering therapy was revealed due to the addition of fenofibrate (p = 0.000) to all groups of patients who were monitored by a lipidologist.

Conclusion. The patients with dyslipidemia and HTG are a complex category of patients who require combined lipid-lowering therapy, which can only be prescribed by a lipidologist. 

1. Aguiar C., Alegria E., Bonadonna R.C., Catapano A.L., Cosentino F., Elisaf M., Farnier M., Ferrières J., Filardi P.P., Hancu N., Kayikcioglu M., Mello E. Silva A., Millan J., Reiner Ž., Tokgozoglu L., Valensi P., Viigimaa M., Vrablik M., Zambon A., Zamorano J.L., Ferrari R. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1-12. doi:10.1016/S1567-5688(15)30001-5.

2. Tsygankova O.V., Ozhiganova N.V., Kashtalap V.V., Bayramova S.S., Latyntseva L.D. Hypertriglyceridemia as a multidisciplinary problem of modern medicine. Complex Issues of Cardiovascular Diseases. 2020;9(4):114-123. doi:10.17802/2306-1278-2020-9-4-114-123. (In Russian)

3. Castelli W.P. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70(19):3H9H. doi:10.1016/0002-9149(92)91083-G.

4. Chepetova T.V., Meshkov A.N. Hypertriglyceridemia: etiology, pathogenesis, diagnostics. Cardiovascular Therapy and Prevention. 2006;5(5):94-100. (In Russian)

5. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, crosssectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015;14:115. doi:10.1186/s12933-015-0268-2.

6. Arutyunov G.P., Boytsov S.A., Voyevoda M.I., Gurevich V.S., Drapkina O.M., Kukharchuk V.V., Martynov A.I., Sergiyenko I.V., Shestakova M.V., Aliyeva A.S., Akhmedzhanov N.M., Bubnova M.G., Galyavich А.S., Gordeyev I.G., Ezhov M.V., Karpov Yu.A., Konstantinov V.O., Nedogoda S.V., Nifontov E.M., Orlova Ya.A., Panov A.V., Sayganov S.A., Skibitskiy V.V., Tarlovskaya E.I., Urazgildeyeva S.A., Khalimov Yu.S. Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics. Rational Pharmacotherapy in Cardiology. 2019;15(2):282-288. (In Russian.) doi:10.20996/1819-6446-2019-15-2-282-2887.

7. Smink P.A., Lambers Heerspink H.J., Gansevoort R.T., de Jong P.E., Hillege H.L., Bakker S.J., de Zeeuw D. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis. 2012;60(5):804-11. doi: 10.1053/j.ajkd.2012.06.017.

8. Hopkins P.N., Heiss G., Ellison R.C., Province M.A., Pankow J.S., Eckfeldt J.H., Hunt S.C. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 2003;108(5):519-523. doi: 10.1161/01.CIR.0000081777.17879.85

9. Yezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S., Balakhonova T.V., Barbarash O.L., Boytsov S.A. et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis, Atherosclerosis and Dyslipidemia. 2017;3:5-22. (In Russian)

10. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M.M., Vlachopoulos C., Wood D.A., Zamorano J.L., Cooney M.T.; ESC Scientific Document Grou2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272.18.